Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label vedolizumab safety and efficacy study in ulcerative colitis and Crohn's disease
NL-OMON43573Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (2 cohorts), sponsored by Takeda. Primary endpoint: Long-term safety. Started Feb 2010; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON43573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43573.